Clinical Trial

Study of CM512 Injection in Subjects With Moderate-to-severe Asthma

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This study is a multicenter, randomized, double-blind, placebo-controlled phase II clinical trial evaluating the efficacy, safety, pharmacokinetics, pharmacodynamics, and immunogenicity of CM512 in subjects with moderate-to-severe asthma.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-06-05.
Status change: Not Yet Recruiting → Recruiting 2025-08-21
Trial Details
NCT Number NCT07011524
Lead Sponsor Keymed Biosciences Co.Ltd
Conditions Asthma
Enrollment 200 participants
Start Date 2025-08-19
Primary Completion 2027-07-21 (estimated)
Study Completion 2027-07-21 (estimated)
Updated on ClinicalTrials.gov 2025-08-28